Wall Street brokerages expect that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings per share of ($0.17) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Evoke Pharma’s earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.19). Evoke Pharma posted earnings per share of ($0.14) in the same quarter last year, which would indicate a negative year-over-year growth rate of 21.4%. The company is scheduled to report its next earnings report on Monday, May 21st.
On average, analysts expect that Evoke Pharma will report full year earnings of $0.11 per share for the current year, with EPS estimates ranging from ($0.42) to $1.16. For the next financial year, analysts anticipate that the business will report earnings of $0.23 per share, with EPS estimates ranging from ($0.83) to $1.85. Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.21.
Shares of EVOK traded down $0.08 during mid-day trading on Friday, hitting $2.12. The stock had a trading volume of 12,930 shares, compared to its average volume of 85,932. The firm has a market cap of $34.08, a price-to-earnings ratio of -2.59 and a beta of 1.38. Evoke Pharma has a fifty-two week low of $1.85 and a fifty-two week high of $4.09.
Several hedge funds and other institutional investors have recently made changes to their positions in EVOK. Creative Planning bought a new stake in shares of Evoke Pharma in the 4th quarter worth approximately $226,000. B. Riley Financial Inc. bought a new stake in shares of Evoke Pharma in the 4th quarter worth approximately $249,000. 683 Capital Management LLC bought a new stake in shares of Evoke Pharma in the 4th quarter worth approximately $258,000. Deutsche Bank AG bought a new stake in shares of Evoke Pharma in the 4th quarter worth approximately $452,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Evoke Pharma by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after purchasing an additional 68,544 shares during the last quarter. 18.42% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Brokerages Expect Evoke Pharma Inc (EVOK) to Announce -$0.17 EPS” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3335248/brokerages-expect-evoke-pharma-inc-evok-to-announce-0-17-eps.html.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.